ENCOD
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
September 24, 2009  |  By ENCOD In 2009

ON THE THERAPEUTIC USE OF LSD

arton1970

Lysergic acid diethylamide (LSD)


History

The psychedelic drug/entheogen LSD was first synthesized by the Swiss chemist Albert Hofmann in the Sandoz (now Novartis) laboratories in Basel, Switzerland in 1938. It was not until five years later on April 19, 1943, that the psychedelic properties were discovered. Widespread therapeutic use of LSD-25 and similar psychedelic drugs began in the 1950s. By 1965, there had appeared in scientific journals more than two thousand papers describing treatment, of thirty to forty thousand patients, with psychedelics (Buckman, 1967). Since then, the literature has continued to grow and now includes book-length works as well as the shorter reports published in journals and anthologies.

Almost all therapists reporting these successes have stated that the incidence of recovery or significant improvement was substantially greater than with other therapies used by them in the past. The treatment typically required much less time and was accordingly less costly for the patient.


Reports on therapeutic use

Types of conditions repeatedly stated to respond favorably to treatment with psychedelics include chronic alcoholism, criminal psychopathy, sexual deviations and neuroses, depressive states, phobias, anxiety neuroses. In addition, psychedelics have been used with autistic children, to make them more responsive and to improve behavior and attitudes; with terminal cancer patients, to ease both the physical pain and the anguish of dying; and with adult schizophrenics, to condense the psychosis temporarily and to help predict its course of development.

Legal status

LSD was put on Schedule 1 of the UN Convention on Psychotropic Substances of 1971. Since then it has been illegal worldwide

Risks

Taking it in dangerous or out of the way places can increase the risk of accidents. Accidents may happen while users are hallucinating.

A sudden shock or fright can send the user into an anxiety or panic attack. If this happens the user should be taken to a quiet place, reassured, told they are safe and that the bad feelings will wear off.

When the effects of LSD have faded, users can feel exhausted, weak and depressed.

Users may experience flashbacks, where parts of a trip are briefly re-lived some time after the event.

LSD can complicate mental health problems such as depression, anxiety and schizophrenia.

Charges from opponents of psychedelic therapy have attributed bias and excessive enthusiasm to workers with the drugs. Certainly, some of the early papers were extravagant, as tends to happen with new therapies. But the time has long passed when psychedelics could be hailed as a panacea; and it should be remarked that the bias of the advocates only rarely approaches that of some “distinguished” critics. Some of these critics seem ideologically and emotionally threatened by psychedelic therapy. This has been especially true of psychiatrists heavily committed to psychoanalysis. Psychedelics emerge at a time when analysis is increasingly under strong attack. Much of the opposition to the drugs is thus understandable, but also unjustifiable.

Finally, psychedelic therapy has been assailed as too dangerous. Very definitely, the evidence does not bear this out; and in fact, when the drugs are administered by those therapists and researchers who are most effective, the “dangers” are negligible. This is borne out by studies involving many thousands of patients and experimental drug subjects.

More information

[ LSD and alcoholism: A clinical study of treatment efficacy

 >http://scholar.google.be/scholar?hl=nl&client=firefox-a&rls=org.mozilla:nl:official&hs=JEq&q=author:%22Ludwig%22+intitle:%22LSD+and+alcoholism:+A+clinical+study+of+treatment+efficacy%22+&um=1&ie=UTF-8&oi=scholarr]
, by AM Ludwig and others,

Therapeutic Applications of LSD and Related Drugs, by Robert E. L. Masters and Jean Houston


More information on the therapeutic use of other psycho-active substances

Previous StoryON THE THERAPEUTIC USE OF IBOGA
Next StoryON THE LACK OF RESEARCH ON ILLICIT DRUGS

Related Articles

  • arton2192
    PRAGUE DEPENALISES USE OF ALL DRUGS
  • arton2187
    DRUG MONEY HELPED SAVE BANKS, SAYS UN DRUG TSAR

Categories

Archives

  • About us
  • Downloads
  • Contact
  • Privacy Policy
  • Legal Notice & Terms of Use
  • Imprint

Copyright ©2018 ThemeFuse. All Rights Reserved

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

REPUBLISHING TERMS

You may republish this article online or in print under our Creative Commons license. You may not edit or shorten the text, you must attribute the article to ENCOD and you must include the author’s name in your republication.

If you have any questions, please email thujer@gmail.com

License

Creative Commons License AttributionCreative Commons Attribution
ON THE THERAPEUTIC USE OF LSD